as attached

Eris Lifesciences Ltd released its Corporate Presentation dated June 23, 2026, outlining its strategic direction and performance. The presentation highlights the company's position among the top-20 Indian pharma companies, with a strong focus on super-specialty segments like Anti-Diabetes and Insulins, where it holds significant market shares. It details robust R&D and manufacturing capabilities, alongside an expanding international business across 70+ countries. The company emphasizes its strategy of leveraged acquisitions, with investments exceeding INR 4,300 crore, to enter and strengthen its presence in high-value therapeutic areas such as Dermatology, Nephrology, and Injectables, signaling strong growth prospects.